FDA speech oversight
This article was originally published in The Tan Sheet
Executive Summary
Pfizer requests two-month extension of comment period "to formulate the most useful input possible" in response to agency's First Amendment inquiry, according to a June 12 filing. "Locating and analyzing pertinent studies and other professional literature...will be a complex and time-consuming effort," the extension request states. Pfizer also "intends to consult with various experts" to address FDA's questions "more thoroughly and effectively." Pfizer, as well as J&J, PhRMA, suggest July 30 deadline be extended to Sept. 30. FDA is seeking input on nine questions, including the constitutionality of its approach to regulating dietary supplement claims (1"The Tan Sheet" May 20, 2002, p. 6)...
You may also be interested in...
FDA speech regulation
Agency will "shortly" publish Federal Register notice extending time for public comment on how FDA regulation of commercial speech complies with First Amendment case law. Original July 30 comment deadline will be extended by 45 days to Sept. 13, with deadline for responses to comments extended to Oct. 28. Several firms, including Pfizer, J&J, requested two-month extension to gather data, consult with experts (1"The Tan Sheet" July 1, 2002, In Brief). Acting FDA Commissioner Lester Crawford, PhD, also solicited public comments in July 3 JAMA...
Supplement Claims Rules v. Drugs, Foods: FDA Opens Free Speech Debate
FDA invites public comments on the constitutionality of its approach to regulating claims for dietary supplements compared with Rx drugs and foods in a notice appearing in the May 16 Federal Register
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.